Chin-Lee Wu, MD, PhD
Chin-Lee Wu, MD, PhD
Associate Professor of Pathology, Harvard Medical School
About Chin-Lee Wu, MD, PhD
Dr. Wu is recognized internationally as a Genitourinary Pathology specialist. He has developed a number of biomarkers to improve diagnosis and prognosis of prostate, kidney and bladder cancers. He consults as needed for particularly difficult urologic pathology specimens encountered by other staff pathologists who do not specialize in genitourinary cancer. Dr. Wu is a member of the Dana Farber-Harvard Cancer Center Prostate and Kidney Cancer Programs, and has his research laboratory in the Pathology Department at Massachusetts General Hospital.
Departments, Centers, & Programs:
Clinical Interests:
- Genitourinary pathology
Treats:
- Adult
Locations
Pathology Associates
55 Fruit Street
Boston, MA 02114-2696
Phone: 617-726-2967
Fax: 617-726-7474
Medical Education
- MD, First Military Medical University
- PhD, Medical College of Wisconsin
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Anatomic Pathology, American Board of Pathology
Accepted Insurance Plans
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Maine Community Health Options (MCHO)
- MassHealth
- Medicare
- Medicare - ACD
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- TriCare
- Tufts Health Plan
- Unicare
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
The Wu laboratory is jointly supported by the departments of urology and pathology at Massachusetts General Hospital. Research is focused on studies of molecular biomarkers in urologic tumors including cancers of the prostate, bladder and kidney. The long-term goal of our studies is to develop new diagnostic methods and therapeutic regimens. A major focus of the lab is to identify gene expression profiles associated with development, diagnosis and prognosis of prostate cancer. We have used laser capture micro-dissection techniques and DNA microarray technology to identify a group of genes whose expression can be used to predict the outcome of patients diagnosed with prostate cancer. We are in the process of developing a new gene-based diagnostic test to guide clinical management of prostate cancer.
Another project in the laboratory is aimed at improving imaging techniques in prostate cancer. Dr. McDougal, Dr. Leo Cheng and I have identified a metabolomic signature of prostate cancer. We are applying this signature to develop an in-vivo imaging technique for patients with prostate cancer. With this new imaging technology, we hope to be able to better stage localized prostate cancer and quantify the volume of prostate cancer in-vivo See details at the Wu Lab. For more information about research concepts, co-authors, and to see a timeline, visit Dr. Wu's profile at the Harvard Clinical and Translational Science Center.
.